EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Telitacicept targets Gd-IgA1 and autoantibody-producing B cells in IgA nephropathy

Qinjie Weng iD, Xinyi Zhu, Hong Ren, Xiao Li, Jingyuan Xie

Nephrology Dialysis Transplantation · 2026

DOI: 10.1093/ndt/gfag001 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, 2026. Verfasst von Qinjie Weng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Autoantibodies, B-Lymphocytes, Immunoglobulin A. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Major International (Regional) Joint Research Program of National Natural Science Foundation of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis and a leading cause of end-stage renal disease for young adults. The key pathogenesis of IgAN involves overproduction of galactose-deficient IgA1 (Gd-IgA1) and anti-Gd-IgA1 antibodies, resulting in formation of circulating immune complexes that deposit in the glomerular mesangium. Consequently, emerging therapeutic strategies for IgAN aim to target and reduce aberrant Gd-IgA1 and its associated immune complexes. This disease-modifying approach confers benefits across multiple stages of IgAN progression, particularly in the early phase to halt irreversible renal damage. B-cell activating factor (BAFF) and proliferation-inducing ligand (APRIL) are critical cytokines that promote the differentiation, development and activation of B cells and plasma cells. Telitacicept, a novel recombinant fusion protein that dual-targets BAFF and APRIL, exhibits considerable therapeutic potential by inhibiting the production of Gd-IgA1 and its autoantibodies. Stage A results of the Phase 3 clinical trial demonstrated that patients in the telitacicept group achieved a 55% reduction in 24-h urinary protein-to-creatinine ratio and stable estimated glomerular filtration rate at Week 39 versus the placebo group, with favorable tolerability and safety. This review summarizes current progresses in targeting Gd-IgA1-producing cells for the treatment of IgAN, with a focus on therapeutic strategies including BAFF/APRIL inhibitors. Furthermore, it delineates the major challenges and future research directions aimed at optimizing these interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGAAutoantibodiesB-LymphocytesImmunoglobulin ARecombinant Fusion ProteinsHumansTumor Necrosis Factor Ligand Superfamily Member 13B-Cell Activating FactorAnimals

Stichwörter der Autor:innen

B cellsBAFF/APRIL inhibitionGd-IgA1IgA nephropathytelicacicept

Substanzen

AutoantibodiesTumor Necrosis Factor Ligand Superfamily Member 13Immunoglobulin AB-Cell Activating FactorRecombinant Fusion ProteinsTNFSF13 protein, humantelitaciceptgalactosyl-deficient IgA1

Autor:innen und Institutionen

  • Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
  • Institute of Nephrology, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.

ORCID-Profile: Qinjie Weng

Förderung

  • National Key Research and Development Program of China
  • Major International (Regional) Joint Research Program of National Natural Science Foundation of China
  • National Natural Science Foundation of China
  • Shanghai Shenkang Hospital Development Center
  • National Facility for Translational Medicine (Shanghai) Open subjects
  • Program of Shanghai Academic/Technology Research Leader
  • Science and Technology Innovation Action Plan of Shanghai Science and Technology Committee
  • Shanghai Municipal Education Commission

Zitieren

APA

Weng, Q., Zhu, X., Ren, H., Li, X., & Xie, J. (2026). Telitacicept targets Gd-IgA1 and autoantibody-producing B cells in IgA nephropathy. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag001

Vancouver

Weng Q, Zhu X, Ren H, Li X, Xie J. Telitacicept targets Gd-IgA1 and autoantibody-producing B cells in IgA nephropathy. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag001

BibTeX
@article{Weng2026,
  author = {Weng, Qinjie and Zhu, Xinyi and Ren, Hong and Li, Xiao and Xie, Jingyuan},
  title = {Telitacicept targets Gd-IgA1 and autoantibody-producing B cells in IgA nephropathy},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfag001}
}
Kostenlos starten →